Moderna to soon release bivalent COVID-19 vaccine
By | translator Alice Kang
22.07.19 12:04:58
가나다라
0
A combo vaccine that targets Omicron BA 1 subvariant… will soon apply for approval
“Showed effect in BA 4 and 5 subvariants as well… can supply bivalent vaccine from the end of August”
Moderna emphasizes the need for Korea to use bivalent vaccine
Moderna is determined to promptly commercialize its new bivalent COVID-19 vaccine “mRNA-1273.214 (214)” in Korea.
On the morning of the 19th, Moderna held a “Moderna’s mRNA technology and strategy in the endemic era” press conference at JW Mariott Hotel. At the conference, the company stated that it can “supply the 214 globally by the end of August, and plans to submit data for its approval in a few days.”
▲(From the left) Hee Soo Kim, Medical Director at Moderna Korea; Paul Burton, Chief Medical Officer at Moderna Global ; Ji-Young Sohn, General Manager of Moderna Korea; Francesca Ceddia, Senior Vice President of Respiratory Vaccines at Moderna Global
The 214 that was developed by Moderna combines a vaccine that targets the original strain and the Omicron variant BA.1. The vaccine achieved superior neutralizing geometric mean titer ratio (GMR) over the current vaccine against the original virus as well as Omicron su
(same@dailypharm.com)
If you want to see the full article, please JOIN US (click)